Artelo Biosciences, Inc.
ARTL Nasdaq
SEC CIK 1621221
Follow Artelo Biosciences
Weekly email: filings, results
Net income
−$1.8M
+43.3% vs same quarter last year
EPS, diluted
−$3.19
Operating cash flow
−$2.6M
+25% vs same quarter last year
Operating income
−$1.8M
+42% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$12.9M |
| FY24 | −$9.8M |
| FY23 | −$9.3M |
| FY22 | −$10.1M |
| FY21 | −$7.4M |
| FY20 | −$4.7M |
| FY19 | −$2.2M |
| FY18 | −$2.3M |
| FY17 | −$234.9K |
| FY16 | −$29.7K |
| FY15 | −$15.2K |
| FY14 | −$15.3K |